350 Queen Street
Level 17
Melbourne, VIC 3000
Australia
61 3 9123 1140
https://www.ampliatx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | CEO, MD & Director | 1.51M | N/A | 1965 |
Mr. Tim Luscombe B.Com., C.A. | Chief Financial Officer | N/A | N/A | N/A |
Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer | N/A | N/A | N/A |
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Secretary | 76.67k | N/A | 1960 |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Amplia Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.